These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 18219812)

  • 61. Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis.
    Putzki N; Kollia K; Woods S; Igwe E; Diener HC; Limmroth V
    Eur J Neurol; 2009 Mar; 16(3):424-6. PubMed ID: 19187261
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
    Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Treatment of refractory epilepsy with natalizumab in a patient with multiple sclerosis. Case report.
    Sotgiu S; Murrighile MR; Constantin G
    BMC Neurol; 2010 Sep; 10():84. PubMed ID: 20863362
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Consensus statement of the Canadian MS CLinics Network on: the use of disease modifying agents in multiple sclerosis.
    Oger J; Freedman M
    Can J Neurol Sci; 1999 Nov; 26(4):274-5. PubMed ID: 10610197
    [No Abstract]   [Full Text] [Related]  

  • 65. Treating multiple sclerosis with natalizumab.
    Iaffaldano P; Lucchese G; Trojano M
    Expert Rev Neurother; 2011 Dec; 11(12):1683-92. PubMed ID: 22091593
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Recent therapeutic strategy for multiple sclerosis].
    Itoyama Y
    Rinsho Shinkeigaku; 2001 Dec; 41(12):1214-7. PubMed ID: 12235841
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Natalizumab therapy for highly active pediatric multiple sclerosis.
    Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
    JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Disease modifying therapies in multiple sclerosis].
    Fukaura H
    Nihon Rinsho; 2014 Nov; 72(11):2015-22. PubMed ID: 25518387
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Classical immunomodulatory therapy in multiple sclerosis: how it acts, how it works.
    Mendes A; Sá MJ
    Arq Neuropsiquiatr; 2011 Jun; 69(3):536-43. PubMed ID: 21755136
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
    J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A practical approach to immunomodulatory therapy for multiple sclerosis.
    Burks JS
    Phys Med Rehabil Clin N Am; 2005 May; 16(2):449-66, ix. PubMed ID: 15893681
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Multiple sclerosis-associated fatigue during disease-modifying treatment with natalizumab, interferon-beta and glatiramer acetate.
    Yildiz M; Tettenborn B; Putzki N
    Eur Neurol; 2011; 65(4):231-2. PubMed ID: 21454981
    [No Abstract]   [Full Text] [Related]  

  • 73. Disease modifying therapies in multiple sclerosis: could a baseline thyroid check-up drive the therapeutic choice between interferon-β and glatiramer acetate?
    Rotondi M; Bergamaschi R; Chiovato L
    Mult Scler; 2014 Dec; 20(14):1918-9. PubMed ID: 24812044
    [No Abstract]   [Full Text] [Related]  

  • 74. Immunomodulatory treatment of multiple sclerosis in Norway.
    Torkildsen Ø; Grytten N; Myhr KM
    Acta Neurol Scand Suppl; 2007; 187():46-50. PubMed ID: 17419828
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Monoclonal antibodies for the treatment of multiple sclerosis].
    Sánchez-Seco VG; Casanova Peño I; Arroyo González R
    Med Clin (Barc); 2014 Dec; 143 Suppl 3():30-4. PubMed ID: 25732947
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [New therapeutic strategies in multiple sclerosis].
    Berger E; Rumbach L
    Rev Med Interne; 1999 Aug; 20 Suppl 3():346s-350s. PubMed ID: 10480185
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients.
    Johnson BH; Bonafede MM; Watson C
    CNS Drugs; 2015 Jun; 29(6):503-10. PubMed ID: 26113055
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Natalizumab in the pediatric MS population: results of the Italian registry.
    Ghezzi A; Moiola L; Pozzilli C; Brescia-Morra V; Gallo P; Grimaldi LM; Filippi M; G GC;
    BMC Neurol; 2015 Sep; 15():174. PubMed ID: 26407848
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response.
    Río J; Tintoré M; Sastre-Garriga J; Nos C; Castilló J; Tur C; Comabella M; Montalban X
    Eur J Neurol; 2012 Jun; 19(6):899-904. PubMed ID: 22289050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.